Although CpG has been reported to be able to significantly enhance the malaria parasite-specific CD4+ T responses and reduce the vaccine dose from 108 to 103 (Pinzon-Charry et al., 2010), the use of CpG as an adjuvant in humans has not been approved. This evidence concerns the gene CD4 and malaria.